ClearPoint Neuro, Inc. (CLPT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-10-29
$10.69+1.23%
Close 2026-10-29 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-10-29
Research Workspace
Put CLPT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Achieve 2026 revenue between $52M and $56M: Comparison needs review.
View ThesisRevenue growth is accelerating — up about 33% over the past year.
View GrowthManagement screens weak on capital allocation, earnings delivery, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 3% on a typical day and fell roughly 64% in its worst 12-month stretch.
View RiskClearPoint Neuro’s IRRAflow integration must convert milestones into revenue and cost synergies. Revenue growth accelerated from 18% to 36% year over year, though the company remains unprofitable. Q3 earnings beat expectations, but revenue fell short of estimates. CLPT trades at 7× sales versus a 3× peer median, near its 11× historical multiple. The price reflects less growth than our forecast, despite that peer premium. The risk is that IRRAflow execution falters; the primary 2026 revenue comparison needs review. Our model puts the next-quarter miss probability near 36%. Peer multiples imply a price about 26% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-29. CLPT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 2 analysts currently covering CLPT (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare CLPT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CLPT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put CLPT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Integrate IRRA flow and realize revenue and cost synergies
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Five defined IRRAflow milestones support integration execution, though AMT-130 approval timing remains potential.
Threatens: Expand clinical trial and regulatory progress with biopharma partners
uniQure trial setback impacts biopharma partnership progress.
Earnings call provides clarity on revenue guidance and growth.